

INFORMATION DISCLOSURE STATEMENT	Docket No. P1101P1	RECEIVED FEB 11 1998	Application No. 09/020,746
	Applicant(s): Avi J. ASHKENAZI		Examiner: C. Kaufman
	Filing Date: February 9, 1998	USPTO CUST. & COMM.	Group Art Unit: 1646

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>CWR</i>	Brojatsch, J. et al. "CAR1, a TNFR-Related Protein, Is a Cellular Receptor for Cytopathic Avian Leukosis-Sarcoma Viruses and Mediates Apoptosis." <i>Cell</i> , Vol. 87 (1996). pp. 845-855.
	Chapman, Barbara. "A region of the 75 kDa neurotrophin receptor homologous to the death domains of TNFR-I and Fas." <i>B.S. Chapman/FEBS Letters</i> , Vol. 374 (1995). pp. 216-220.
	Pan, G. et al. "An Antagonist Decoy Receptor and a Death Domain-Containing Receptor for TRAIL." <i>Science</i> , Vol. 277 (1997). pp. 815-818
	Rabidezeh, S. et al. "Induction of Apoptosis by the Low-Affinity NGF Receptor." <i>Science</i> , Vol. 261 (1993). pp. 345-348.
<i>CWR</i>	Tartaglia, L. et al. "A Novel Domain within the 55kd TNF Receptor Signals Cell Death." <i>Cell</i> , Vol. 74 (1993). pp. 845-853.

EXAMINER <i>Clara M. Kif</i>	DATE CONSIDERED <i>10/28/03</i>
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO-A820 (also form PTO-1449)	SHEET 1 OF 1

INFORMATION DISCLOSURE STATEMENT	Docket No. P1101P1	RECEIVED FEBRUARY 12, 1998	Application No. 09/020,746
	Applicant(s): Avi J. ASHKENAZI		Examiner: C. Kaufman
	Filing Date: February 9, 1998	03-12-22 FILED-23	Group Art Unit: 1647/646

U.S. PATENT DOCUMENTS

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
CW		6,313,269	11/06/2001	Keith C. Deen et al.			
		08/916,625	08/22/1997	Keith C. Deen et al.			
		08/853,684	05/09/1997	Keith C. Deen et al.			
CW		60/041,230	03/14/1997	Keith C. Deen et al.			

FOREIGN PATENT DOCUMENTS

REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
CML	WO 0077191	12/21/2000	WIPO PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER	<i>Clay M. Kuykendall</i>	DATE CONSIDERED	<i>10/28/03</i>
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

INFORMATION DISCLOSURE STATEMENT	Docket No. P1101PI	RECEIVED	Application No. 09/020,746
	Applicant(s): Avi J. ASHKENAZI	03-12-2003	Examiner: C. Kaufman
	Filing Date: February 9, 1998	Group Art Unit: 1646	

#2

U.S. PATENT DOCUMENTS

Examiner Initial	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
CJL		2002/0160446 A1 (serial no. 09/811,088)	10/31/2002	Douglas A. Holtzman			
		2002/0048785 A1 (serial no. 09/757,421)	04/25/2002	Douglas A. Holtzman			
		09/712,726	11/14/2000	David Gearing			
		08/843,652	04/16/1997	Douglas A. Holtzman			
		08/843,651	04/16/1997	Douglas A. Holtzman			
ar		08/820,364	03/12/1997	David Gearing	/		

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER <i>CJL</i>	DATE CONSIDERED <i>10/28/03</i>
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO-A820 (also form PTO-1449) SHEET 1 OF 1	

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark OfficeAtty Docket No.
P1101P1Serial No.
09/020,746

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant
Ashkenazi et al.Filing Date
09 Feb 1998Group
1647 1646

U.S. PATENT DOCUMENTS

Citaminer Cited Materials		Document Number	Date	Name	Class	Subclass	Filing Date
Clu	1	4,855,235	08.08.89	Takahashi et al.			
Clu	2	5,153,118	06.10.92	Wright, Jr. et al.			
Clu	3	5,158,885	27.10.92	Bradstock et al.			
Clu	4	6,417,328	09.07.02	Alnemri			

FOREIGN PATENT DOCUMENTS

Citaminer Cited Materials		Document Number	Date	Country	Class	Subclass	Translation Yes No
Clu	5	WO 02/053727	11.07.02	PCT			<i>Opposited</i>
Clu	6	WO 92/01047	23.01.92	PCT			
Clu	7	WO 92/20791	26.11.92	PCT			
Clu	8	WO 93/00109	07.01.93	PCT			
Clu	9	WO 93/06213	01.04.93	PCT			
Clu	10	WO 93/11236	10.06.93	PCT			
Clu	11	WO 93/19172	30.09.93	PCT			
Clu	12	WO 95/01438	12.01.95	PCT			
Clu	13	WO 95/15388	08.06.95	PCT			

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

Clu	14	Carter et al., "Antibody Engineering Using Very Long Template-Assembled Oligonucleotides" <u>Methods: A Companion to Methods in Enzymology</u> 3(3):183-192 (Dec 1991)
Clu	15	Chunharapai and Kim, "Generation of Monoclonal Antibodies to Chemokine Receptors" <u>Methods in Enzymology</u> 288:15-27 (1997)
Clu	16	Ellis, S., "Recognition of HLA-B27 and Related Antigen by a Monoclonal Antibody" <u>Human Immunology</u> 5:49-59 (1982)
Clu	17	Emery et al., "Osteoprotegerin Is a Receptor for the Cytotoxic Ligand Trail" <u>Journal of Interferon and Cytokine Research</u> (Abstract No. 2.17 from the 7th Intl. Tumor Necrosis Factor Congress May 17-21) 18(5):A-47 (May 1998)
Clu	18	Fishwild et al., "High-Avidity Human IgGk Monoclonal Antibodies From a Novel Strain of Minilocus Transgenic Mice" <u>Nature Biotechnology</u> 14(7):845-851 (Jul 1996)
Clu	19	Glassy, M., "Production methods for generating human monoclonal antibodies" <u>Human Antibodies & Hybridomas</u> 4(4):154-165 (Oct 1993)
Clu	20	Handbook of Monoclonal Antibodies, Ferrone et al. eds., Park Ridge, NJ:Noyes Publications, pps. 302-359 and Chapter 22 (1985)
Clu	21	Hoogenboom, "Designing and optimizing library selection strategies for generating high-affinity antibodies" <u>Trends in Biotechnology</u> 15(2):62-70 (Feb 1997)
Clu	22	Jones, Y., "Cytokine Receptor Complexes Versus Cell Adhesion Interactions - Upping the Affinity" (Abstract no. M11.OA.002 presented at the XVIIth IUCr Congress & General Assembly held in Glasgow, Scotland on August 4th-13th, 1999.) pps. 133
Clu	23	Kabat et al. <u>Sequences of Proteins of Immunological Interest</u> (NIH Publn. No. 91-3242), 5th edition

Citaminer	<i>Clau M. Kay</i>	Date Considered <i>10/28/03</i>
-----------	--------------------	------------------------------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

28 Feb 2003

Sheet 2 of 2

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. <u>P1101P1</u>	Serial No. 09/020,746
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Ashkenazi et al.	
				Filing Date 09 Feb 1998	Group <u>1647 1646</u>
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
<i>Cuy</i>	24	Lasky et al., "DNA sequence analysis of the type-common glycoprotein-D genes of herpes simplex virus types 1 and 2" <u>DNA</u> 3(1):23-29 (1984)			
	25	Mendez et al., "Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice" <u>Nature Genetics</u> 15:146-156 (Feb 1997)			
	26	Neri et al., "Engineering recombinant antibodies for immunotherapy" <u>Cell Biophysics</u> 27(1):47-61 (Aug 1995)			
	27	Olsson and Kaplan, "Human-human hybridomas producing monoclonal antibodies of predefined antigenic specificity" <u>Proc. Natl. Acad. Sci. USA</u> 77(9):5429-5431 (1980)			
	28	Peterson, N., "Recombinant antibodies: alternative strategies for developing and manipulating murine-derived monoclonal antibodies" <u>Laboratory Animal Science</u> 46(1):8-14 (Feb. 1996)			
	29	Pluckthun., "Antibodies From Escherichia coli." <u>The Pharmacology of Monoclonal Antibodies: Handbook of Experimental Pharmacology</u> , Rosenberg and Moore, eds., Berlin:Springer-Verlag, Chapter 11, Vol. 113:269-315 (1994)			
	30	Smith et al., "Cardiac Glycoside-Specific Antibodies in the Treatment of Digitalis Intoxication" <u>Antibodies in Human Diagnosis and Therapy</u> pp. 365-389 (1977)			
	31	Soderlind et al., "Phage display technology in antibody engineering: design of phagemid vectors and in vitro maturation systems" <u>Immunological Reviews</u> 130:109-124 (Dec 1992)			
	32	Steinitz et al., "EB virus-induced B lymphocyte cell lines producing specific antibody" <u>Nature</u> 269(5627):420-422 (Sep 29, 1977)			
<i>Cuy</i>	33	Vaughan et al., "Human Antibodies With Sub-nanomolar Affinities Isolated From a Large Non-immunized Phage Display Library" <u>Nature Biotechnology</u> 14:309-314 (1996)			
	34	Winter et al., "Making antibodies by phage display technology" <u>Annual Review of Immunology</u> 12:433-455 (1994)			
Examiner <i>Clara M. Kip</i>				Date Considered <u>10/28/03</u>	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					